Stevanato Group Spa Stock News

Stevanato Group S.p.A. (NYSE:STVN ) Q1 2025 Results Conference Call May 8, 2025 8:30 AM ET Company Participants Lisa Miles - SVP & Investor Relations Franco Stevanato - Chairman & Chief Executive Officer Marco Dal Lago - Chief Financial Officer Conference Call Participants Matt Larew - William Blair Paul Knight - KeyBanc Michael Ryskin - Bank of America David Windley - Jefferies Tejas Savant - ...

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced that it will participate in three upcoming investor conferences. Wednesday, May 14, 2025, at 5:00 p.m. (PT) – Fireside chat at the 2025 Bank of Americ...

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the first quarter of 2025. First Quarter 2025 Highlights (comparisons to prior-year period) Revenue for the first quarter of...

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the first quarter of 2025 on Thursday, May 8, 2025, at 6:30 a.m. (ET). Conference call and webcast: The Compa...

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in the KeyBanc Capital Markets Healthcare Forum taking place from Tuesday, March 18 to Wednesday, March 19, 2025. The Company...

Stevanato's 2024 revenue reached €1.1 billion, surpassing analyst expectations. This growth was driven by Biopharmaceutical and Diagnostic Solutions, despite a challenging year with inventory issues. Investments in expanding facilities in Latina and Fishers aim to meet rising product demand, and a significant sales increase is expected. Supportive CAPEX investment in different GEO provides down...

Stevanato Group S.p.A. (NYSE:STVN ) Q4 2024 Earnings Conference Call March 6, 2025 8:30 AM ET Company Participants Lisa Miles - SVP, IR Franco Stevanato - Chairman and CEO Marco Dal Lago - CFO Conference Call Participants Michael Ryskin - Bank of America Matt Larew - William Blair Patrick Donnelly - Citi David Windley - Jefferies Pete Lukas - CJS Securities Anna Snopkowski - KeyBanc Tejas Savan...

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the fourth quarter and fiscal year 2024. Fourth Quarter and Full-Year 2024 Highlights (comparisons to prior-year period) Rev...